News

Tuesday, 24. February 2026 | Filed under Company News

New data demonstrate medical and health‑economic benefits of digital sleep apnea screening

— Analysis shows significant patient benefit and substantial cost‑saving potential through early digital screening for obstructive sleep apnea (OSA)

— Digital, smartphone‑based solutions enable systematic, low‑threshold screening

— More than 20 percent of the adult population in Germany are affected by obstructive sleep apnea requiring treatment

Obstructive sleep apnea (OSA) is a widespread, chronic condition that often remains undiagnosed for long periods and can lead to serious comorbidities such as hypertension or diabetes. Sleep apnea episodes are breathing pauses of up to one minute, during which the body receives less oxygen. These pauses can occur several hundred times per night and may have substantial health consequences. The risk of stroke is doubled and the risk of heart attack is fourfold increased. This can lead to severe health outcomes and significant costs for healthcare systems. Studies indicate that more than 20% of the adult population in Germany suffer from obstructive sleep apnea requiring treatment.

News from akampion

We are pleased to announce that akampion has further strengthened its senior team with the addition of two highly experienced consultants — Francina Agosti, PhD, a trained neuroscientist, and Almut Gebhard, MSc, a trained biologist.

This move further expands akampion’s core strength: senior-level strategic communications advisory in situations where communications become truly value-critical — including financings, key data readouts, strategic milestones, leadership transitions, and early company-building phases.

Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATP-R13 in Atopic Dermatitis and Strengthens Patent Protection

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma
Positive opinion from the European Patent Office strengthens patent protection of ATP-R13
Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications

Atopia Therapeutics, a leader in the development of innovative, disease-modifying therapies for allergic and atopic diseases, today announced significant progress in the development of its lead compound ATP-R13. The Company has successfully generated new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral treatment for atopic dermatitis, an allergic condition commonly known as eczema.